technology
Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026
SHANGHAI and HONG KONG , Oct. 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ( "Antengene" , SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that it will present the latest preclinical results of its novel costimulatory T cell engager (Cos-TCE) platform in a Rapid Oral Abst
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Delhi’s new master plan can soothe parking pains
Hindustan Times
World News | Indian Ambassador to Kazakhstan Calls for ‘connectivity in Its True Sense’, Urges Shift from AI Talks to Joint Projects
Latestly
World News | “I'm Hurting, but Care Deeply About E”: Musk's Partner Shivon Zilis Confirms Sudden Split, Hopes to Be “great Coparents”
Latestly
LIGHT AI PROVIDES QUICKSCAN™ STREP A PRODUCT DEVELOPMENT UPDATE
Techdash.in
CNG drivers, check this before your next refill: IGL’s new system can flag your car at the pump
Business News India